Melissa Tovar
Family · Corpus Christi, TXNPI 1164187084
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 635 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 635 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- AbbVie$1K
- Boehringer Ingelheim$523
- Amgen$522
- Pfizer$447
- plus $4K from 29 others
What the payments were for
- Food & beverage$10,084100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 145 | $2,207 |
| Lilly USA, LLC | 115 | $1,642 |
| AbbVie | 84 | $1,198 |
| Boehringer Ingelheim | 21 | $523 |
| Amgen | 41 | $522 |
| Pfizer | 35 | $447 |
| Bayer | 23 | $399 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $229 |
| Exact Sciences | 13 | $210 |
| Idorsia Pharmaceuticals US Inc | 14 | $209 |
| Dexcom, Inc. | 13 | $202 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $192 |
| Astellas Pharma US Inc | 8 | $165 |
| Sanofi-aventis U.S. LLC | 5 | $158 |
| Amarin Pharma, Inc. | 8 | $151 |
| Lundbeck LLC | 8 | $146 |
| Ardelyx, Inc. | 6 | $132 |
| Merck | 8 | $114 |
| GSK | 7 | $109 |
| AstraZeneca | 7 | $104 |
| Nevro Corp. | 4 | $99 |
| Phathom Pharmaceuticals, Inc. | 6 | $95 |
| Mylan Specialty L.p. | 2 | $88 |
| Organogenesis Inc. | 1 | $85 |
| Sumitomo Pharma America, Inc. | 4 | $69 |
| Mannkind Corporation | 3 | $53 |
| Novartis | 3 | $52 |
| Currax Pharmaceuticals LLC | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,097 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $175,308 |
| MounjaroTirzepatide | 96 | $115,435 |
| JardianceEmpagliflozin | 86 | $113,243 |
| RybelsusSemaglutide | 54 | $72,259 |
| LinzessLinaclotide | 41 | $37,907 |
| EliquisApixaban | 41 | $34,562 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $29,509 |
| MyrbetriqMirabegron | 27 | $27,162 |
| TrulicityDulaglutide | 13 | $24,486 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $22,305 |
| FarxigaDapagliflozin Propanediol | 31 | $21,766 |
| Bydureon BciseExenatide Microspheres | 11 | $16,316 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $15,445 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $15,143 |
| JanuviaSitagliptin Phosphate | 13 | $13,822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,207 | $247,566201 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,642 | $139,921109 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $523 | $118,48497 claims |
| AbbVieLinzess | $1,198 | $37,90741 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $104 | $37,21143 claims |
| PfizerEliquis | $447 | $34,56241 claims |
| Astellas Pharma US IncMyrbetriq | $165 | $27,16227 claims |
| MerckJanuvia, Belsomra | $114 | $25,13038 claims |
| GSKTrelegy Ellipta | $109 | $22,30524 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $158 | $9,98912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Corpus Christi
- Stephanie RodriguezCorpus Christi$159K
- Katie MontgomeryCorpus Christi$29K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.